SEARCH

Biocon, Mylan ink pact for generic insulin products

Our Bureau
Comment   ·   print   ·  
A file photo of Biocon CMD, Kiran Mazumdar Shaw.
A file photo of Biocon CMD, Kiran Mazumdar Shaw.

Biocon has tied up with Mylan for development and commercialisation of generic versions of its three insulin analog products.

According to Biocon’s Chairman and Managing Director, Kiran Mazumdar-Shaw, “Mylan is a natural preferred partner for our portfolio of generic Insulin analogs and this collaboration further strengthens our existing successful partnership.”

Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus), Lispro (the generic version of Eli Lilly’s Humalog) and Aspart (the generic version of Novo Nordisk’s NovoLog).

Mylan CEO Heather Bresch said, “This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products.”

Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Mylan will have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the European Union and the European FTA countries through a profit sharing arrangement with Biocon.

anil.u@thehindu.co.in

(This article was published on February 14, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.

Comments:

This article is closed for comments.
Please Email the Editor

DATA BANK

Exchange Rate

Dollar Spot Forward Rate

Open-Ended Mutual Funds

MCX-SX Currency Futures

NSE Currency Futures


O
P
E
N

close

Recent Article in Companies

Robert Bosch in white goods deal

Robert Bosch will acquire Siemens’ 50 per cent stake in the household appliances’ joint venture, BSH Bosch, for a total value of €3 bill... »

Comments to: web.businessline@thehindu.co.in. Copyright © 2014, The Hindu Business Line.